Xbrane Enters Into Licencing Agreement With Vaxiion

The agreement enables Xbrane Bioscience to distribute and sell the protein expression system for both research and commercial purposes, in addition to utilising the system for their in-house protein production services business.

The company claims that protein expression in the Rhamex System is tightly regulated at the individual cell level, via rhamnose induction, and enables production of high yields of more bioactive and correctly folded proteins per production run. The mechanism of induction allows for slower, more uniform production of proteins compared to the all-or-nothing induction mechanisms characteristic of other systems.

The Rhamex System commonly uses the gram-negative bacteria E coli as production host cell but is amenable to use in other gram-negative hosts.

Maria Alriksson, CEO of Xbrane, said: “We aim to help companies improve their protein production using the Rhamex System and our extensive knowledge about expression of host-toxic proteins. The Rhamex System is a complement to our existing product, Xbrane Lemo System and an important step in our growth strategy. We have high expectations for this system and are very happy that we now can launch the Rhamex System to the global market.”